Legend Biotech is ending the week with a 42% single-day surge and a month that has rewritten the stock's positioning narrative entirely.
The catalyst is concrete. Legend presented initial Phase 1 data for LB2501 — its in vivo CAR-T candidate — in non-Hodgkin lymphoma at EHA 2026, catching the market by surprise. For a name whose entire bull case rests on CAR-T innovation beyond Carvykti, a late-breaking oral presentation at one of haematology's flagship conferences is a signal that the pipeline is broader than the bears had credited. The stock has now gained 54% over the past month and 23% over the week alone, closing Tuesday at $36.28.
The short positioning story has been just as dramatic as the price move. Shorts have been retreating steadily since mid-April, when SI stood near 24% of free float — a notably elevated level. By the end of May that had compressed to around 17%, and the data release accelerated the exit. At 17.2% of float, short interest remains high in absolute terms, but the trend is unambiguous: over 7 million shares of short position have been closed in six weeks, a 26% reduction in one month. The borrow market has also loosened considerably. Cost to borrow is now 0.36%, down 36% on the week, and availability has expanded sharply to 226% of short interest — meaning more than two shares are available in the lending pool for every one currently borrowed. The squeeze dynamic that was plausible at April's levels has materially softened.
Options traders have swung firmly behind the move. The put/call ratio has fallen to 0.40, below its 20-day average of 0.43 and near the 52-week low of 0.37 hit just yesterday. That is almost a full standard deviation below the mean — call demand is running well ahead of put hedging. The picture is one of growing conviction on the upside rather than defensive positioning, a stark reversal from where the market stood a month ago when PCR was consistently running above 0.47.
The Street moved quickly to respond on Wednesday. UBS raised its target to $49 from $31 while maintaining Buy, and HC Wainwright lifted to $65 from $50 with the same rating. Both actions were filed the morning after the data dropped. The mean analyst target across all coverage now stands at $56.39 — 55% above where the stock trades. Bulls point to Carvykti's commercial trajectory in multiple myeloma and the early but notable LB2501 data as evidence the pipeline deserves a richer multiple. TD Cowen holds the dissenting view, maintaining Hold with a $29 target, citing a market the stock has already blown through. Morgan Stanley remains constructive at Overweight with a $48 target. EV/EBITDA has re-rated sharply, up over 14 points over the past month, reflecting the market's reassessment of what the pipeline is worth. On earnings momentum, LEGN ranks in the 97th percentile on the 30-day window and 90th on EPS surprise — forward estimates have been moving aggressively higher.
On the institutional side, Fidelity (FMR) added 1.29 million shares as of April 30, and Deerfield, Suvretta, and Point72 all added meaningfully through Q1. First Beijing Investment and Two Sigma both initiated or greatly expanded positions in Q1 as well. The ownership base has been building quietly, and that institutional accumulation now has a catalyst behind it. The one recent insider trade on record — a CEO sale of roughly $87k in March at $8.77 — is almost irrelevant at today's price and volume context.
The next scheduled event is Q2 earnings on August 21. Between now and then, the focus narrows to whether the EHA data holds up under peer and investor scrutiny, and whether Carvykti's commercial volumes show the supply improvements the bears have been flagging. With shorts still holding 17% of the float and borrow now cheap and abundant, any further clinical catalysts would still find meaningful short-side fuel to burn through.
See the live data behind this article on ORTEX.
Open LEGN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
